Bibliografie tematiche / Targeted alpha therapy

Indice

Articoli di riviste
Tesi
Libri
Capitoli di libri
Atti di convegni
Rapporti di organizzazioni

Letteratura scientifica selezionata sul tema "Targeted alpha therapy"

Autore: Grafiati

Pubblicato: 4 giugno 2021

Ultima modifica: 31 gennaio 2023

Cita una fonte nei formati APA, MLA, Chicago, Harvard e in molti altri stili

Scegli il tipo di fonte:

Consulta la lista di attuali articoli, libri, tesi, atti di convegni e altre fonti scientifiche attinenti al tema "Targeted alpha therapy".

Accanto a ogni fonte nell'elenco di riferimenti c'è un pulsante "Aggiungi alla bibliografia". Premilo e genereremo automaticamente la citazione bibliografica dell'opera scelta nello stile citazionale di cui hai bisogno: APA, MLA, Harvard, Chicago, Vancouver ecc.

Puoi anche scaricare il testo completo della pubblicazione scientifica nel formato .pdf e leggere online l'abstract (il sommario) dell'opera se è presente nei metadati.

Articoli di riviste sul tema "Targeted alpha therapy"

HANAOKA, Hironari, e Tsutomu TAKEUCHI. "Interferon ^|^alpha;-targeted therapy". Japanese Journal of Clinical Immunology 36, n. 4 (2013): 181–88. http://dx.doi.org/10.2177/jsci.36.181.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Zalutsky, M. R., e G. Vaidyanathan. "383 TARGETED ALPHA THERAPY". Radiotherapy and Oncology 102 (marzo 2012): S195. http://dx.doi.org/10.1016/s0167-8140(12)70332-8.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Kozempel, Jan, e Martin Vlk. "Nanoconstructs in Targeted Alpha-Therapy". Recent Patents on Nanomedicine 4, n. 2 (11 marzo 2015): 71–76. http://dx.doi.org/10.2174/1877912305666150102000549.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Morgenstern, Alfred, Frank Bruchertseifer e Christos Apostolidis. "Targeted Alpha Therapy with 213Bi". Current Radiopharmaceuticalse 4, n. 4 (1 ottobre 2011): 295–305. http://dx.doi.org/10.2174/1874471011104040295.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Majkowska-Pilip, Agnieszka, Weronika Gawęda, Kinga Żelechowska-Matysiak, Kamil Wawrowicz e Aleksander Bilewicz. "Nanoparticles in Targeted Alpha Therapy". Nanomaterials 10, n. 7 (13 luglio 2020): 1366. http://dx.doi.org/10.3390/nano10071366.

Testo completo

Abstract (sommario):

Recent advances in the field of nanotechnology application in nuclear medicine offer the promise of better therapeutic options. In recent years, increasing efforts have been made on developing nanoconstructs that can be used as carriers for immobilising alpha (α)-emitters in targeted drug delivery. In this publication, we provide a comprehensive overview of available information on functional nanomaterials for targeted alpha therapy. The first section describes why nanoconstructs are used for the synthesis of α-emitting radiopharmaceuticals. Next, we present the synthesis and summarise the recent studies demonstrating therapeutic applications of α-emitting labelled radiobioconjugates in targeted therapy. Finally, future prospects and the emerging possibility of therapeutic application of radiolabelled nanomaterials are discussed.

Gli stili APA, Harvard, Vancouver, ISO e altri

Vaidyanathan, Ganesan, e Michael R. Zalutsky. "Targeted therapy using alpha emitters". Physics in Medicine and Biology 41, n. 10 (1 ottobre 1996): 1915–31. http://dx.doi.org/10.1088/0031-9155/41/10/005.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Allen, Barry J., Chand Raja, Syed Rizvi, Yong Li, Wendy Tsui, David Zhang, Emma Song et al. "Targeted alpha therapy for cancer". Physics in Medicine and Biology 49, n. 16 (31 luglio 2004): 3703–12. http://dx.doi.org/10.1088/0031-9155/49/16/016.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Sgouros, George. "Alpha-particles for targeted therapy". Advanced Drug Delivery Reviews 60, n. 12 (settembre 2008): 1402–6. http://dx.doi.org/10.1016/j.addr.2008.04.007.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Morgenstern, A., K. Abbas, F. Bruchertseifer e C. Apostolidis. "Production of Alpha Emitters for Targeted Alpha Therapy". Current Radiopharmaceuticalse 1, n. 3 (1 settembre 2008): 135–43. http://dx.doi.org/10.2174/1874471010801030135.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

J. Allen, Barry. "Future Prospects for Targeted Alpha Therapy". Current Radiopharmaceuticalse 4, n. 4 (1 ottobre 2011): 336–42. http://dx.doi.org/10.2174/1874471011104040336.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Più fonti

Tesi sul tema "Targeted alpha therapy"

Song, Emma Yanjun Clinical School St George Hospital Faculty of Medicine UNSW. "Targeted alpha therapy for epithelial ovarian cancer". Awarded by:University of New South Wales. Clinical School - St George Hospital, 2007. http://handle.unsw.edu.au/1959.4/40874.

Testo completo

Abstract (sommario):

Purpose: Control of micrometastatic ovarian cancer in the peritoneal cavity remains a major objective in post-surgical treatment. The purpose of this project was to investigate the efficacy and toxicity of targeted alpha therapy (TAT) for ovarian cancer in vitro and in vivo in animal models and to select the optimal targeting vector for an ovarian cancer clinical trial. Animal models of ovarian, breast and prostate cancer were developed and for further TAT; a phase I melanoma clinical trial was supported, paving the way for an ovarian cancer clinical trial. Methods: The expression of the turnor-associated antigens (Her2, MUC1, uPAfuPAR) on cancer cell line, animal model xenografts and human ovarian cancer tissue was tested by immunostaining. MTS and TUNEL assays were used to evaluate cell killing of alpha conjugates in monolayer and spheroids. Toxicity and maximum tolerance doses for different vectors were tested and determined in vivo. Pharmacokinetics was studied for different time points and different parameters. The antiproliferative effect of 213Bi-C595 and 213Bi-PAI2 was tested at 9 days post-peritoneal cell inoculation of the ovarian cancer cell line OVCAR3. The treatment efficacy of 213Bi-Herceptin was tested at a 2 days post-subcutaneous breast cancer cell BT474 inoculation. Mice were injected (i.p) with various concentrations of alpha conjugates (AC). Changes in cancer progression were assessed by girth size and tumor size. Results: uPA/uPAR and MUCI are expressed on ovarian cancer cell lines and more than 45% ovarian cancer tissue, while HER2 was only positive in one cell line and was positive in less than 15% of ovarian cancer tissues. The ACs can target and kill cancer cells in vitro in a dose dependent fashion. TUNEL positive cells were found after incubation with the different ACs. PAI2 and C595 vectors were selected for in vivo ascites model study of OVCARJ cell with high expression. Delayed and acute toxicity in animal models showed that radiation nephropathy was the cause of body weight loss. Biodistribution studies showed that kidney was the major uptake organ. L-lysine can reduce kidney uptake for 213Bi-PAI2, but no significant differences were found. A single ip injection of 213Bi-C595 or 213Bi-PAI2 can inhibit ascites growth, whereas, 213Bi-Herceptin can inhibit breast cancer growth in a nude mice model. Conclusion: 213Bi labelled targeting vectors can specifically target ovarian cancer cells in vitro and inhibit tumor growth in vivo. These ACs may be useful agents for the treatment of ovarian cancer at the minimum residual disease stage.

Gli stili APA, Harvard, Vancouver, ISO e altri

Andrews, Shannon. "FOLATE CONJUGATED DENDRIMERS FOR TARGETED ANTICANCER THERAPY". VCU Scholars Compass, 2014. http://scholarscompass.vcu.edu/etd/3497.

Testo completo

Abstract (sommario):

Anticancer therapeutics are often limited to suboptimal doses due to their lack of selectivity for tumor cells and resultant damage to healthy tissue. These limitations motivated researchers to develop tumor-specific delivery systems for improved therapeutic efficacy and reduced unintended cytotoxicity. Polyamidoamine dendrimers offer an ideal platform for designing targeted therapeutics with tunable characteristics that optimize pharmacokinetic behavior and targeting specificity. Ligand conjugation to dendrimer provides the biochemical interaction necessary to activate tumor-specific receptors for receptor-mediated endocytosis and effective internalization of polyplexes. Tumor-specific receptors overexpressed in carcinomas, like folate receptor-alpha (FOLRα), are targeted by ligand-conjugated dendrimer to allow enhanced internalization of dendrimer and its therapeutic cargo. We examined the cellular trafficking dynamics and potential of folate-conjugated dendrimer for nucleic acid delivery in vitro. Results show folate-conjugation to G4 PAMAM dendrimer (G4FA) confers enhanced uptake in FOLRα-positive tumor cells. Cells internalize G4FA in a receptor-dependent manner with specificity for FOLRα-positive tumor cells.

Gli stili APA, Harvard, Vancouver, ISO e altri

Pashaeinejad, Masoumeh Physics Faculty of Science UNSW. "Targeted alpha-therapy:cell survival determination in melanoma tumours using Monte Carlo calculations". Awarded by:University of New South Wales. Physics, 2006. http://handle.unsw.edu.au/1959.4/23996.

Testo completo

Abstract (sommario):

This study investigates the Monte Carlo calculations of cell survival in metastatic subcutaneous melanoma cancer tumours. To achieve this goal, a Monte Carlo program called SLAB.FOR was developed by Prof. David Charlton. The program randomly places alphas from 213Bi in the medium, which is a cancer cell sized micro dosimeter with a SiO2 converter on the top and Si as the sensitive volume. Then the Monte Carlo program calculates the energy deposited by alphas and their chord length and also the dose deposited in the sensitive volume. To be able to use this program, some information was taken from phase one of a clinical trial conducted by the Centre of Experimental Radiation Oncology (CERO) in 2001. During the course of this study the administered activities on tumours with different diameters are determined. Using this information the number of alpha particles going through each m3 of the tumour was found. Based on this number, the program SLAB.FOR was run for different administered activities in the tumours. The output of the program yielded the energy deposited and the number of hits by the alpha particles as they go through the tumours. The output data was also used to calculate the cell survival values, energy and hit distribution probabilities. The cell survival values were then used to plot the cell survival curves. They were plotted against dose, number of hits and injected activity per volume of the tumours. These data were also used to plot the energy and hit distribution probability curves. Our results show that survival is dependent on the diameter of the cell and decreases when the dose deposited in the tumour increases. The survival also has a relationship with the number of hits that a cell receives and it also depends on the injected activity to the volume. The survival decreases as the number of hits and injected activity increases. Our results confirmed what was stated in the clinical trial conducted by the Centre of Experimental Radiation Oncology (CERO) in 2001.

Gli stili APA, Harvard, Vancouver, ISO e altri

Toro-Gonzalez, Miguel. "LANTHANIDE-BASED CORE-SHELL NANOPARTICLES AS MULTIFUNCTIONAL PLATFORMS FOR TARGETED RADIONUCLIDE THERAPY AND MULTIMODAL MOLECULAR IMAGING". VCU Scholars Compass, 2018. https://scholarscompass.vcu.edu/etd/5647.

Testo completo

Abstract (sommario):

Lanthanide phosphate (LnPO4) and lanthanide vanadate (LnVO4) nanoparticles (NPs) are promising platforms for theranostic applications because of their chemical stability, low solubility, low toxicity, and unique luminescence and magnetic properties. Motivated by the high radiation resistance and ability to host actinides of naturally occurring lanthanide-based compounds, LnPO4 and LnVO4 NPs were studied as radionuclide carriers for targeted radionuclide therapy using in vivoα-generators, 223Ra, 225Ac, and 227Th. The implementation of these radionuclides has shown potential for the treatment of micrometastases and solid tumors as well as challenges in the retention of decay daughters at the target site to minimize unwanted radiotoxicity. LnPO4 and LnVO4 core-shell NPs doped with either 156Eu, a “cocktail” of 85, 89Sr and 156Eu, or in vivo α-generators 223Ra, 225Ac, and 227Th were synthesized in aqueous media. In vitro retention of radionuclides was investigated by dialyzing the radionuclide-doped NPs suspensions against deionized water and quantifying the activity in dialysate aliquots over time. The crystal structure, morphology, physical stability, luminescence and magnetic properties were evaluated. Partial retention of 156Eu (~70–95%) and 85, 89Sr (>80%) was evidenced in LnPO4 core NPs, while 227Th and decay daughters were quantitatively retained in LaPO4 core + 2 shells NPs (>99%). Gd0.8Eu0.2VO4 and GdVO4 core-shell NPs showed partial retention of 223Ra (~75%), 225Ac (75–95%), 227Th (>96%), and decay daughters. Radionuclide retention was influenced by the lanthanide concentration, crystal structure, and number of shells. The partial retention of radionuclides in both LnPO4 and LnVO4 core-shell NPs may enhance the treatment efficacy while minimizing unwanted toxicity. LnVO4 core and core-shell NPs have potential as carriers of short-lived radionuclides for both diagnostic and therapeutic applications. Emission intensities were higher for LnVO4 with respect to LnPO4 NPs, whereas no significant difference was observed in the magnetic susceptibilities. GdVO4 core NPs displayed enhancement of the signal intensity in T1-weighted images. This work evidences the promising application of both LnPO4 and LnVO4 NPs as platforms for targeted radionuclide therapy and multimodal molecular imaging.

Gli stili APA, Harvard, Vancouver, ISO e altri

Petitprin, Aurélie. "Le RAFT-RGD radiomarqué avec un émetteur °- comme nouvel agent de radiothérapie interne vectorisée". Thesis, Grenoble, 2013. http://www.theses.fr/2013GRENS002/document.

Testo completo

Abstract (sommario):

Le RAFT-RGD radiomarqué avec un émetteur β- comme nouvel agent de radiothérapie interne vectorisée. L'intégrine αvβ3 est fortement impliquée en oncogenèse à travers son rôle dans la néoangiogenèse tumorale, dans la prolifération et la survie des cellules cancéreuses et dans le processus métastatique. L'intégrine αvβ3 est exprimée faiblement dans la plupart des tissus. Par contre, elle est fortement exprimée par les cellules endothéliales activées lors de l'angiogenèse et par les cellules de nombreux types de cancers invasifs. Ces caractéristiques font de l'intégrine αvβ3 une excellente cible pour l'imagerie et la thérapie de ces tumeurs. Le RAFT-RGD (Regioselectively Addressable Functionalized Template-(cyclo-[RGDfK])4) est un derivé polypeptidique constitué de quatre peptides cyclo-RGD (spécifiques de l'intégrine αvβ3) fixés sur un groupe porteur RAFT. Le RAFT-RGD cible spécifiquement l'intégrine αvβ3 in vitro et in vivo et permet la détection par imagerie nucléaire ou par fluorescence de tumeurs exprimant αvβ3 sur des modèles précliniques. Le RAFT-RGD un excellent vecteur potentiel pour cibler les tumeurs exprimant αvβ3 et pour y délivrer des traitements, que ce soit des molécules de chimiothérapie ou des radionucléides de thérapie. Cette étude est la première à évaluer le potentiel thérapeutique du RAFT-RGD radiomarqué avec un émetteur β- sur un modèle de souris Nude porteuses de tumeurs exprimant l'intégrine αvβ3. Une injection de 37 MBq de 90Y-RAFT-RGD ou de 177Lu-RAFT-RGD permet de ralentir significativement la croissance de tumeurs exprimant l'intégrine αvβ3 par rapport aux souris contrôles non traitées ou traitées avec la même activité de la molécule de contrôle non spécifique de la cible, le RAFT-RAD. En comparaison, une injection de 30 MBq de 90Y-RAFT-RGD ne permet pas de ralentir la croissance de tumeurs n'exprimant pas l'intégrine αvβ3. Le RAFT-RGD présente un bon potentiel pour le traitement de tumeurs exprimant l'intégrine αvβ3 lorsqu'il est radiomarqué avec des émetteurs β-. Mots clés : intégrine αvβ3, RAFT-RGD, ciblage tumoral, radiothérapie interne vectorisée
Β- emitters radiolabeled RAFT-RGD as new agents for internal targeted radiotherapy. The αvβ3 integrin is known to play an important role in tumor-induced angiogenesis, tumor proliferation, survival and metastasis. Because of its overexpression on neoendothelial cells such as those present in growing tumors, as well as on tumor cells of various origins, αvβ3 integrin is an attractive molecular target for diagnosis and therapy of the rapidly growing and metastatic tumors. A tetrameric RGD-based peptide, regioselectively addressable functionalized template-(cyclo-[RGDfK])4 (RAFT-RGD), specifically targets integrin αvβ3 in vitro and in vivo. RAFT-RGD has been used for tumor imaging and drug targeting. This study is the first to evaluate the therapeutic potential of the β- emitters radiolabeled tetrameric RGD peptide RAFT-RGD in a Nude mouse model of αvβ3-expressing tumors. An injection of 37 MBq of 90Y-RAFT-RGD or 177Lu-RAFT-RGD in mice with αvβ3-positive tumors caused a significant growth delay as compared with mice treated with 37 MBq of 90Y-RAFT-RAD or 177Lu-RAFT-RAD or untreated mice. In comparison, an injection of 30 MBq of 90Y-RAFT-RGD had no efficacy for the treatment of αvβ3-negative tumors. 90Y-RAFT-RGD and 177Lu-RAFT-RGD are potent αvβ3-expressing tumor targeting agents for internal targeted radiotherapy. Keys words : integrin αvβ3, RAFT-RGD, tumour targeting, internal targeted radiotherapy

Gli stili APA, Harvard, Vancouver, ISO e altri

Doligalski, Michael Lawrence. "Design and Development of Peptidomimetic Ligands for Targeting Radiopharmaceuticals, Imaging Probes, and Immunotherapeutics in Oncologic Disease". Scholar Commons, 2016. http://scholarcommons.usf.edu/etd/6492.

Testo completo

Abstract (sommario):

Cancer is a leading cause of morbidity and mortality in the developed world. While much has been learned about these diseases in the last few decades, one of the main barriers to widespread advancement is the heterogeneity of cancer biology. A growing body of evidence supports the idea that certain protein receptors are overexpressed on the surface of tumor cells as compared to normal tissues. These extracellular biomarkers provide a unique opportunity to selectively target the tumor with both imaging and therapeutic modalities. The research in this dissertation focuses on targeting proteins on the tumor cell surface with peptidomimetic ligands. Following a description of various extracellular receptors, chapter one discusses targeting ligands designed to specifically and selectively bind these receptors. It reviews recent literature on targeted alpha-particle therapy and ends with an explanation of the advantages of peptide ligands. Three distinct approaches to imaging and therapeutic modalities are then discussed in subsequent chapters. First, a peptide ligand was designed to target radionuclides to malignant melanoma cells in an effort to develop companion radiotherapeutics and diagnostic imaging agents. The second research project describes the synthesis of a novel antagonist peptide ligand with conjugated near infrared dye, and its utility for real-time intraoperative guidance during pancreatic adenocarcinoma resection. Finally, the last chapter describes how the relatively new field of immunomodulatory effectors may be enhanced by their derivatization with peptide targeting ligands.

Gli stili APA, Harvard, Vancouver, ISO e altri

Kostova, Vesela. "Shiga toxin targeted strategy for chemotherapy and cancer immunotherapy application using copper-free « Click » chemistry". Thesis, Sorbonne Paris Cité, 2015. http://www.theses.fr/2015USPCB144.

Testo completo

Abstract (sommario):

Pas de résumé
Recently targeted therapies appeared as attractive alternatives to classical antitumoral treatments. The approach, developed on the concept of targeting drug to cancer cells, aims to spear normal tissues and decrease the side effects. This doctoral dissertation focuses on developing new anticancer targeted treatments in the field of chemotherapy and cancer immunotherapy by exploiting an original targeting moiety, the B subunit of Shiga toxin (STxB). Its specific properties, such as, recognition with its receptor Gb3 overexpressed in cancer cells or in antigen-presenting cells, its unconventional intracellular trafficking, guided the choice of this protein as targeting carrier. This project is based in the use of copper-free Huisgen [3+2] cycloaddition as a coupling method, which led to successful preparation of various conjugates for their respective applications. The concept was first validated by STxB-biotin conjugate. The high yield of the reaction and the compatibility between the targeting carrier and the chemical ligation promoted the design of conjugates for chemotherapy and immunotherapy. Two therapeutical optimizations of previously developed strategy in STxB drug targeting delivery were investigated: synthesis of multivalent drug-conjugates and synthesis of conjugates containing a highly potent anticancer agent. Both approaches exploited three anticancer agents: SN38, Doxorubicin and Monomethyl auristatin F. The disulfide spacer, combined with various self-immolative systems, insured drug release. Two cytotoxic conjugates STxB–doxorubicin (STxB-Doxo) and STxB-monomethyl auristatin F (STxB-MMAF) were obtained in very high yield and demonstrated strong tumor inhibition activity in the nanomolar range on Gb3-positive cells. Based on the results the STxB-MMAF conjugate was investigated on a mouse model. The project aimed also to develop STxB bioconjugates for vaccine applications. Previous studies used B subunit as a targeting carrier coupled to an antigenic protein in order to induce a more potent immune response against cancer. The conjugates were prepared using a commercial linker, requiring modifying the antigen at first place, or by oxime ligation, where slightly acidic conditions promoted the coupling. Thus, the work presented herein proposed an alternative ligation via copper-free click chemistry especially for more sensitive antigenic proteins. Various types of conjugates were synthesised and investigated for their immune stimulation properties. The STxB targeting strategy was also applied to the development of a new vaccine based on coupling the targeting carrier to alpha-GalCer, one of the most potent immune stimulating agents known. The work focused on the synthesis of functionalised alpha-Galcer with an azide handle

Gli stili APA, Harvard, Vancouver, ISO e altri

Kannengießer, Stefanie [Verfasser], e Thomas [Akademischer Betreuer] Fanghänel. "Optimization of the Synthesis of Ac-225-labelled DOTA-Radioimmunoconjugates for Targeted Alpha Therapy, based on Investigations on the Complexation of Trivalent Actinides by DOTA / Stefanie Kannengießer ; Betreuer: Thomas Fanghänel". Heidelberg : Universitätsbibliothek Heidelberg, 2013. http://d-nb.info/1177148838/34.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Gruntman, Alisha. "A Translational Pathway for Recombinant Adeno-Associated Virus Human Gene Therapy: From Target Identification and Animal Modeling of the Disease to Non-Human Primate and Human Studies". eScholarship@UMMS, 2011. http://escholarship.umassmed.edu/gsbs_diss/882.

Testo completo

Abstract (sommario):

Many steps go into developing a clinical viral gene therapy. The course starts with appropriate disease selection and moves through the many hurdles of in-vitro testing, animal model validation and proof-of-concept studies, all the way through pre-clinical large animal studies. In this thesis, I propose to outline the process of developing a translation pathway for a gene therapy using recombinant adeno-associated virus (rAAV). I will expand on this outline using data that I have generated during the course of my Ph.D. that ranges from animal model validation all the way through pre-clinical vector stability studies. Two disease models will be discussed throughout this thesis, Cockayne Syndrome (CS) and Alpha-1 Antitrypsin Deficiency (AATD). Cockayne Syndrome is a rare autosomal recessive genetic disorder involving mutations in either the CSA or CSB gene, leading to defects in DNA repair. Clinically this presents as progressive degeneration of the central nervous system, retina, cardiovascular system, and cochlea, which leads to mental retardation, post-natal growth defects, ocular abnormalities, and shortened life expectancy. Alpha-1 antitrypsin is a serine protease inhibitor largely produced in the liver that mainly functions to inhibit neutrophil elastase within the lung. AATD leads to an increased risk of emphysema, with shortened life expectancy, and also results in accumulations of mutant AAT polymers in the liver, sometimes leading to liver failure. Using these two disease models I will outline the upstream and downstream pre-clinical work as well as the transition to clinical trials of a rAAV based gene therapy.

Gli stili APA, Harvard, Vancouver, ISO e altri

Testo completo

Abstract (sommario):

Gli stili APA, Harvard, Vancouver, ISO e altri

Libri sul tema "Targeted alpha therapy"

Chŏn, Yang-suk. Chongyang ŭi sansŏnghwa e ŭihan HIF-1[alpha] kwabarhyŏn kijŏn kyumyŏng kwa saeroun hangam chʻiryo tʻaget ŭi palgul =: Mechanism of HIF-1[alpha] overexpression in acidified tumor and novel target for anticancer therapy. [Seoul]: Pogŏn Pokchibu, 2007.

Cerca il testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Rai, Samarpit, Zachariah G. Goldsmith, Michael E. Lipkin e Glenn M. Preminger. Ureteric stones. A cura di John Reynard. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199659579.003.0026.

Testo completo

Abstract (sommario):

Acute renal colic is a common presentation to the emergency department. It is estimated that about 12% of men and 5% of women will have at least one symptomatic stone by the age of 70. Renal colic has an annual incidence 16 cases per 10,000 per year, and a lifetime incidence of 2–5%. In the year 2000, there were over 600,000 emergency room visits for urolithiasis listed as the primary diagnosis in the United States alone. In this chapter, acute pharmacologic management of patients diagnosed with ureteral stones will be outlined. The pharmacology and clinical efficacy for narcotic and non-narcotic analgesics will be reviewed. In addition, medical expulsive therapy using alpha blockers and other agents will be extensively reviewed, in order to provide a targeted approach to the pharmacologic management of patients diagnosed with acute renal colic secondary to a ureteral stone.

Gli stili APA, Harvard, Vancouver, ISO e altri

Cassidy, Jim, Donald Bissett, Roy A. J. Spence OBE, Miranda Payne, Gareth Morris-Stiff e Madhumita Bhattacharyya. Gynaecological cancers. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199689842.003.0020_update_001.

Testo completo

Abstract (sommario):

Genitourinary cancers examines the malignancies arising in the kidney, ureter, bladder, prostate, testis, and penis. Renal cancer has high propensity for systemic spread, largely mediated by overexpression of vascular endothelial growth factor (VEGF). Treatments include surgery, immunotherapy, and targeted therapy. Wilms tumour, a childhood malignancy of the kidney, warrants specialist paediatric oncology management to provide expertise in its unique pathology, staging, and treatment, often with surgery and chemotherapy. Cancer of the bladder and ureters, another tobacco related cancer, may present as either superficial or invasive disease. The former is managed by transurethral resection and intravesical therapy. The latter may require radical surgery, preoperative chemotherapy, or radiotherapy. Prostate cancer, the commonest male cancer, is an androgen dependent malignancy. It has attracted controversy with regards to PSA screening, and potential over treatment with radical prostatectomy. Division into low, intermediate, and high risk disease according to tumour grade, stage, and PSA helps in deciding best treatment, antiandrogen therapy for metastatic disease, radiotherapy and adjuvant hormone therapy for locally advanced disease, either surgery or radiotherapy for early intermediate risk disease, and active monitoring for low risk cases. Testicular cancer divides according to pathology into seminoma, nonseminomatous germ cell tumours (NSGCT), and mixed tumours, the latter two frequently producing tumour markers, alpha-fetoprotein (AFP) and/or human chorionic gonadotrophin (HCG). Stage I disease is managed by inguinal orchidectomy and surveillance or adjuvant chemotherapy. More advanced disease is managed by chemotherapy, with high probability of cure in the majority. Penile cancer, often HPV related, can be excised when it presents early, but delay in presentation may lead to regional and systemic spread with poor prognosis.

Gli stili APA, Harvard, Vancouver, ISO e altri

De Backer, Daniel, e Patrick Biston. Vasopressors in critical illness. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199600830.003.0034.

Testo completo

Abstract (sommario):

Vasopressors are used in various shock states to correct hypotension, aiming at restoring or improving organ and tissue perfusion. Vasopressor therapy may be associated with excessive vasoconstriction, but also metabolic and other side-effects. Hence, the ideal target for arterial pressure remains undetermined. Adrenergic agents remain the most commonly used vasopressor agents. Adrenergic agents increase arterial pressure through stimulation of alpha-adrenergic receptors. The effects of the different adrenergic agents differ mostly due to variable associated beta-adrenergic effects. Epinephrine and norepinephrine are strong and equipotent vasopressor agents. Their impact on outcome is as yet unanswered, but there is no sign that epinephrine might be associated with better outcomes. Accordingly, norepinephrine is the adrenergic agent of choice, especially in patients with cardiogenic shock. Vasopressin is a non-adrenergic vasopressor acting via V1 receptor stimulation, with weak vasopressor effects in normal conditions, but markedly increased vascular tone in shock states, especially in septic shock. Splanchnic vasoconstriction may occur. Arginine vasopressin at low doses appears to be a promising alternative to adrenergic agents, but its exact place is not yet well defined.

Gli stili APA, Harvard, Vancouver, ISO e altri

Capitoli di libri sul tema "Targeted alpha therapy"

Mastren, Tara. "Targeted Alpha Therapy". In Rare Earth Elements and Actinides: Progress in Computational Science Applications, 277–83. Washington, DC: American Chemical Society, 2021. http://dx.doi.org/10.1021/bk-2021-1388.ch013.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Seidl, Christof, e Reingard Senekowitsch-Schmidtke. "Targeted Alpha Particle Therapy of Peritoneal Carcinomas". In Therapeutic Nuclear Medicine, 557–67. Berlin, Heidelberg: Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/174_2012_678.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Chaudhri, M. Anwar, M. Nasir Chaudhri, Qamar Nadeem e Qaiser Jabbar. "Production of Ac-225 with Cyclotrons for Generating Bi-213 for Targeted Alpha Therapy". In IFMBE Proceedings, 686–87. Berlin, Heidelberg: Springer Berlin Heidelberg, 2009. http://dx.doi.org/10.1007/978-3-642-03474-9_193.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Zheng, Yifan, Yoonsuk Huh, Qianqian Su, Jiaming Wang, Yunduan Lin, Kai Vetter e Youngho Seo. "Collimatorless Scintigraphy for Imaging Extremely Low Activity Targeted Alpha Therapy (TAT) with Weighted Robust Least Squares (WRLS)". In Medical Image Computing and Computer Assisted Intervention – MICCAI 2020, 803–11. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-59728-3_78.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Schultz, Michael K., Jean-Pierre Pouget, Frank Wuest, Bryce Nelson, Jan Andersson, Sarah Cheal, Mengshi Li et al. "Radiobiology of Targeted Alpha Therapy". In Nuclear Medicine and Molecular Imaging, 380–403. Elsevier, 2022. http://dx.doi.org/10.1016/b978-0-12-822960-6.00093-4.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Chatterjee, Sayandev, Kenneth R. Czerwinski, Hilary A. Fitzgerald, Andrew L. Lakes, Zuolei Liao, Russell C. Ludwig, Katie M. McBride e Vladislav P. Vlasenko. "Delivery of radiopharmaceuticals and theranostic agents: targeted alpha therapy". In Novel Platforms for Drug Delivery Applications, 349–404. Elsevier, 2023. http://dx.doi.org/10.1016/b978-0-323-91376-8.00012-4.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abbasi, Akbar, Hesham M.H. Zakaly e Fatemeh Mirekhtiary. "Radium-223 and Actinium-225 α-Emitter Radiopharmaceuticals in Treatment of Metastatic Castration-Resistant Prostate Cancer". In Radiopharmaceuticals - Current Research for Better Diagnosis and Therapy. IntechOpen, 2022. http://dx.doi.org/10.5772/intechopen.99756.

Testo completo

Abstract (sommario):

In recent decades, multiple radiopharmaceutical conjugates have been tested and shown to be efficacious in treating metastasized castration-resistant prostate cancer (mCRPC). Several types of research have been published on the therapeutic use of α-emitter radiopharmaceuticals, and several authors suggested their treatment superiority. One of the suggested methods is targeted alpha therapy. In this method, alpha radiation delivers energy to cancer cells and the tumor microenvironment while minimizing toxicity to surrounding tissues. In this chapter, the alpha emitter radiopharmaceutical applications in castration-resistant prostate cancer patients were investigated. Hence, we studied the 223Ra and 225Ac α-emitter radiopharmaceuticals application method and distribution of dose throughout human body organs.

Gli stili APA, Harvard, Vancouver, ISO e altri

"Current Status of PSMA Targeted Alpha Therapy in Prostate Cancer Patients". In The Evolution of Radionanotargeting towards Clinical Precision Oncology: A Festschrift in Honor of Kalevi Kairemo, a cura di Thabo Lengana e Mike Sathekge, 255–64. BENTHAM SCIENCE PUBLISHERS, 2022. http://dx.doi.org/10.2174/9781681088655122010023.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

"Bone Targeted Radionuclide Therapy in Russia From Beta- to Alpha- Emitters". In The Evolution of Radionanotargeting towards Clinical Precision Oncology: A Festschrift in Honor of Kalevi Kairemo, a cura di N. G. Seleva, V. V. Krylov e T. Yu Kochetova, 368–83. BENTHAM SCIENCE PUBLISHERS, 2022. http://dx.doi.org/10.2174/9781681088655122010034.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Constanzo, Julie, Clara Diaz Garcia-Prada e Jean-Pierre Pouget. "Clonogenic assay to measure bystander cytotoxicity of targeted alpha-particle therapy". In Methods in Cell Biology. Elsevier, 2022. http://dx.doi.org/10.1016/bs.mcb.2022.08.005.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Atti di convegni sul tema "Targeted alpha therapy"

Tafreshi, Narges K., Nella C. Delva, Christopher J. Tichacek, Michael L. Doligalski, Darpan N. Pandya, Nikunj B. Bhatt, HyunJoo Kil et al. "Abstract 5198: Targeted alpha particle therapy for uveal melanoma". In Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-5198.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Hasegawa, S., e HK Li. "PO-110 Targeted alpha-therapy for gastric cancer metastasized to liver in mice". In Abstracts of the 25th Biennial Congress of the European Association for Cancer Research, Amsterdam, The Netherlands, 30 June – 3 July 2018. BMJ Publishing Group Ltd, 2018. http://dx.doi.org/10.1136/esmoopen-2018-eacr25.635.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Schmidtlein, Charles Ross, Matthew K. Maroun, Andrzej Krol, Howard Gifford, Lisa Bodei, Joseph O'Donoghue, Ida Häggström e Yuesheng Xu. "A deblurring/denoising corrected scintigraphic planar image reconstruction model for targeted alpha therapy". In Biomedical Applications in Molecular, Structural, and Functional Imaging, a cura di Barjor S. Gimi e Andrzej Krol. SPIE, 2021. http://dx.doi.org/10.1117/12.2584736.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Bruchertseifer, F., L. Krolicki, J. Kunikowska, H. Koziara, B. Krolicki, M. Jakucinski, D. Pawlak, A. Apostolidis e A. Morgenstern. "Targeted alpha therapy of recurrent glia tumors: clinical experience with 225 Ac-Substance-P". In NuklearMedizin 2020. © Georg Thieme Verlag KG, 2020. http://dx.doi.org/10.1055/s-0040-1708255.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Tworowska, Izabela, Ebrahim S. Delpassand, Julien Torgue, Farah Shanoon, Jason Hurt e Rodolfo Nunez. "Abstract CT159: First-in-human dose escalation of AlphaMedixTMfor targeted alpha-emitter therapy of neuroendocrine tumors". In Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-ct159.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Eriksson, Sophie E., Erika Elgström, Sture Lindegren e Tom Bäck. "Abstract 834: Formation of DNA double-strand breaks in colon tumors after targeted alpha therapy with211At-mAb". In Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-834.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Hasegawa, Sumitaka, e Huizi Keiko Li. "Abstract 5343: Experimental targeted alpha-particle therapy against liver metastasis of HER2-positive gastric cancer in mice". In Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-5343.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Rold, Tammy L., Nkemakonam C. Okoye, Thomas P. Quinn e Timothy J. Hoffman. "Abstract 5344: Treatment efficacy of212Pb-RM2 targeted alpha therapy in human prostate cancer cell lines: Anin vitroinvestigation". In Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-5344.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Labadie, Kevin P., Donald K. Hamlin, Aimee Kenoyer, Sara K. Daniel, Alan F. Utria, Andrew D. Ludwig, Heidi L. Kenerson et al. "Abstract 928: Glypican-3 targeted thorium-227 alpha therapy reduces tumor burden in an orthotopic xenograft model of hepatocellular carcinoma". In Proceedings: AACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7445.am2021-928.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Hu, Meiduo, John Forbes, Ryan Simms, Yaryna Storozhuk, Eric Burak e John Valliant. "Abstract LB130: Combination of IGF-1R targeted alpha therapy with Olaparib results in synergistic efficacy against colorectal and lung cancer xenografts". In Proceedings: AACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7445.am2021-lb130.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Rapporti di organizzazioni sul tema "Targeted alpha therapy"

Sgouros, George. Therapy of Ovarian Carcinoma by Targeted Delivery of Alpha-Particles Using Immunoliposomes Capable of Retaining Alpha-Emitting Daughters. Fort Belvoir, VA: Defense Technical Information Center, ottobre 2005. http://dx.doi.org/10.21236/ada448269.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Ma, Jiao, Lanyin Li, Taiping Liao, Weidong Gong e Chunyin Zhang. Efficacy and safety of 225Ac-PSMA-617-targeted alpha therapy in metastatic castration-resistant prostate cancer:a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, settembre 2021. http://dx.doi.org/10.37766/inplasy2021.9.0103.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Offriamo sconti su tutti i piani premium per gli autori le cui opere sono incluse in raccolte letterarie tematiche. Contattaci per ottenere un codice promozionale unico!